Morris Nejat MD NY Allergist Specializing in Allergy and Allergy Triggers is a Board Certified Pediatrician and an NY Allergist in New York and Midtown and Downtown New York with information on allergy asthma and triggers Morris Nejat for NY allergy, NYC Allergist and Manhattan Allergy treatment and therapy in NYC new york city. NY allergist asthma ny allergy ny allergy dust mites cockroach pollen grass weed count sinus nasal polyps testing skin shots allergyshots NYC new york city allergist asthma ny allergist allergy nyc  allergy dust mites cockroach pollen grass weed count sinus nasal polyps testing skin shots allergyshots Morris Nejat MD Allergist in Allergy Testing, Specializing in Allergy and Allergy Triggers is a Board Certified Pediatrician Allergist in New York and Midtown and Downtown New York with information on allergy asthma sinus and triggers Morris Nejat Arthur Lubitz Feingold Finegold Gregory Pollack Cliff Bassett. Health Insurance Medicare Medicaid Aetna USHC Allmerica Financial AmeriChoice of NJ AmeriHealth Administrators Anthem Healthcare of NY BC/BS BC/BS HMO Beech Street Network Center Care Chickering Claims Administrators Child Health Plus Cigna First Health Network GHI Great West Healthsource HIP Home Care Industry Horizon of NJ Horizon of NY Insurance Design Administrators (IDA) Local Insurances Magnacare MasterCare Medicaid w/Medicare Medicare Multiplan New England Financial NY Government Employee One Health Care Network Oxford PHCS Network PHS Network Pomco Prudential Select Pro Unicare United Healtcare 1199 32-BJ. All insurance accepted. Medication therapy flonase advair claritine clarityne claritin patanol and allergy medication from board certified allergist clarinex clarinext allegra zyrtec glaxo nasonex nasanex.

Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H₁-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction. Olopatadine is devoid of effects on alpha-adrenergic, dopamine, muscarinic type 1 and 2, and seratonin receptors. Following topical ocular administration in man, olopatadine was shown to have low systemic exposure. Two studies in normal volunteers (totaling 24 subjects) dosed bilaterally with olopatadine 0.15% ophthalmic solution once every 12 hours for 2 weeks demonstrated plasma concentrations to be generally below the quantitation limit of the assay (<0.5 ng/ml). Samples in which olopatadine was quantifiable were typically found within 2 hours of dosing and ranged from 0.5 to 1.3 ng/ml. The half-life in plasma was approximately 3 hours, and ellimination was predominantly through renal excretion. Approximately 60-70% of the dose was recovered in the urine as parent drug. Two metabolites, the mono-desmethyl and the N-oxide, were detected at low concentrations in the urine. Results from conjunctival antigen challenge studies demonstrated that olopatadine HCl ophthalmic solution 0.1%, when subjects were challenged with antigen both initially and up to 8 hours after dosing, was significantly more effective than its vehicle in preventing ocular itching associated with allergic conjunctivitis.

Olopatadine HCl ophthalmic solution 0.1% is indicated for the temporary prevention of itching of the eye due to allergic conjunctivitis.

Hypersensitivity to any component of this product.

For topical use only. Not for injection. Patients should be instructed not to instill olopatadine HCl ophthalmic solution 0.1% while wearing contact lenses.

Information for the Patient: To prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use.

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Olopatadine administered orally was not carcinogenic in mice and rats in doses up to 500 mg/kg/day and 200 mg/kg/day, respectively. Based on a 40 mul drop size, these doses were 78,125 and 31,250 times higher than the maximum recommended ocular human dose (MROHD). No mutagenic potential was observed when olopatadine was tested in an in vitro bacterial reverse mutation (Ames) test, an in vitro mammalian chromosome aberration assay or an in vivo mouse micronucleus test. Olopatadine administered to male and female rats at oral doses of 62,500 times MROHD level resulted in a slight decrease in the fertility index and reduced implantation rate; no effects on reproductive function were observed at doses of 7800 times the maximum recommended ocular human use level.

Pregnancy Category C: Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however no adequated and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

Nursing Mothers: Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when olopatadine HCl ophthalmic solution 0.1% is administered to a nursing mother.

Pediatric Use: Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

Olopatadine is used for prevention of itching of the eye due to allergic conjunctivitis.

Inform physician if you are pregnant or nursing.

Do not instill while wearing contact lenses.

May cause headache, burning or stinging, dry eye, foreign body sensation, redness or inflammation of the eyes, lid swelling and itching, general weakness, cold syndrome, sore throat, rhinitis, sinusitis and tast disturbance.

Instill twice daily at 6 to 8 hour intervals.

Contact DrNejat@NYAllergy.com with questions or comments about the content on this web site.
Please read our Disclaimer

Copyright © 2000- 2008, Web-Identities.net
For sales and development please contact the Web-Identities Sales